Physician profile
Marcia E Ward
NPI 1073736252
$4,505.75
in general payments reported to CMS, 2019-2025
25 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $867 · 2023: $1,294 · 2024: $1,199 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $490.24 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $468.97 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $381.64 | 2023-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $331.38 | 2021 | |
| Abbvie INC. | $243.15 | 2023 | |
| Scpharmaceuticals INC. | $220.45 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.95 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $208.58 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $193.90 | 2023-2025 | Quviviq, Tryvio |
| Abbott Laboratories | $140.11 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Sumitomo Pharma America, INC. | $125.40 | 2024 | Myfembree |
| Biohaven Pharmaceuticals, INC. | $124.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Otsuka America Pharmaceutical, INC. | $121.84 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $121.34 | 2024 | Ingrezza |
| Edwards Lifesciences Corporation | $119.01 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $114.05 | 2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $112.79 | 2025 | |
| Urovant Sciences INC | $109.51 | 2021 | |
| Novo Nordisk INC | $106.61 | 2021 | |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.73 | 2025 | |
| Alnylam Pharmaceuticals INC. | $84.51 | 2021 | |
| Coloplast Corp | $27.81 | 2023 | Titan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcia Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.